Ce projet vise à élucider davantage le mode d’action de certains produits élaborés par ProMetic BioSciences inc. sur certaines cellules myéloïdes humaines en relation avec une réponse cellulaire impliquée dans un nombre grandissant de maladies humaines. Il s’agit d’un stress du réticulum endoplasmique (RE), un organite cellulaire impliqué dans la synthèse des protéines. Cette dernière […]

Heart failure (HF) is a condition that develops after the heart becomes damaged or weakened. HF occurs when the pumping action of the heart is not strong enough to move blood around, especially during increased activity or under stress. In addition, the heart muscle may not relax properly to accommodate the flow of blood back […]

The ability to impede/reduce complication of the damaged heart presents a major challenge in the treatment of cardiovascular diseases. Complications include heart failure, which has a high mortality even with current treatments. The use of a new drug to stimulate protection of the heart during an ongoing myocardial infarct and long term changes leading to […]

We recently developed a rapid and cost-effective pre-clinical technology that is well suited for precision medicine –the ex ovo chicken embryo ChorioAllantoic Membrane (CAM) assay. Our goal is to perform a pilot study that combines tumor genotyping data and the use of personalized CAMavatars, to predict drug sensitivity in renal cancer patients and to test […]

Fibroproliferative disorders are a/the leading cause of morbidity and mortality worldwide. A large group of interstitial lung diseases (ILD) can cause progressive scarring of lung tissues, affecting the ability to breathe. Idiopathic Pulmonary Fibrosis (IPF) is one of the major forms of ILD and is characterized by a progressive decline in lung function. Although the […]